A practical reference on peptide backbone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-16 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
=== Soluble (sRAGE) === The soluble form of RAGE (sRAGE) only includes the extracellular domain and lacks both the transmembrane and cytoplasmic domains. sRAGE can be generated through two primary mechanisms:
The Singaporean military, one of the smallest but most technologically advanced in Southeast Asia, consists of the Army, the Navy, the Air Force and the Digital and Intelligence Service. It is seen as the guarantor of the country's independence, translating into Singapore culture, involving all citizens in the country's defence. The government spent 2.7% of the country's GDP on the military in 2024, the highest in the region. After its independence, Singapore had only two infantry regiments commanded by British officers. Considered too small to provide effective security for the new country, the development of its military forces became a priority. In addition, in October 1971, Britain pulled its military out of Singapore, leaving behind only a small British, Australian and New Zealand force as a token military presence. A great deal of initial support came from Israel, a country unrecognised by Singapore's neighbouring Muslim-majority nations of Malaysia and Indonesia. The Israel Defense Forces (IDF) commanders were tasked by the Singapore Government to create the Singapore Armed Forces (SAF) from scratch, and Israeli instructors were brought in to train Singaporean soldiers. Military courses were conducted according to the IDF's format, and Singapore adopted a system of conscription and reserve service based on the Israeli model. Singapore still maintains strong security ties with Israel and is one of the biggest buyers of Israeli arms and weapons systems, with one recent example being the MATADOR anti-tank weapon.
=== Side effects === Citicoline has a very low toxicity profile in animals and humans. Clinically, doses of 2000 mg per day have been observed and approved. Minor transient adverse effects are rare and most commonly include stomach pain and diarrhea.
Sources: en.wikipedia.org
==== History ==== Early measurements of thorium isomers were performed via gamma ray spectroscopy, producing the 29.5855 keV excited state of 229Th, and measuring the difference in emitted gamma ray energies as it decays to either the 229mTh (90%) or 229Th (10%) isomeric states. In 1976, Kroger and Reich sought to understand coriolis force effects in deformed nuclei, and attempted to match thorium's gamma-ray spectrum to theoretical nuclear shape models. To their surprise, the known nuclear states could not be reasonably classified into different total angular momentum quantization levels. They concluded that some states previously identified as 229Th actually arose from a spin-3/2 nuclear isomer, 229mTh, with a remarkably low excitation energy. At that time the energy was inferred to be below 100 eV, purely based on the non-observation of the isomer's direct decay. However, in 1990, further measurements led to the conclusion that the energy is almost certainly below 10 eV, making it one of the lowest known isomeric excitation energies. In the following years, the energy was further constrained to 3.5±1.0 eV, which was for a long time the accepted energy value. Improved gamma ray spectroscopy measurements using an advanced high-resolution X-ray microcalorimeter were carried out in 2007, yielding a new value for the transition energy of 7.6±0.5 eV, corrected to 7.8±0.5 eV in 2009. Earlier attempts to observe emitted photons had been doomed by a failure to consider two consequences of this higher energy:
Survodutide (BI 456906) is an experimental peptide that works as a dual glucagon/GLP-1 receptor agonist. Unlike other dual GLP-1/glucagon dual agonists, it is a glucagon analog rather than an analog of oxyntomodulin. It is developed by Boehringer Ingelheim as a weight loss drug. Survodutide is a twincretin having dual glucagon-like peptide-1 and glucagon receptor agonist activity, conceptually based on endogenous peptide oxyntomodulin. In a meta-analysis involving data from 3 randomized controlled trials having 1088 patients, 4- 11 months use of survodutide at doses 2.4-4.8 mg / week was associated with on an average 7-9% reduction in body weight from baseline. This translates to around 9-15kg of body weight reduction from baseline. Gastrointestinal side effects were the predominant side effects, were mild and dose dependent, as has been noted with other incretin based therapies. In adults with obesity and at-risk MASLD, survodutide was statistically and clinically superior to placebo in reducing MRI-PDFF–assessed liver fat content (LFC) and body weight.
The 2008 war between Russia and Georgia has been a source of political controversy and conflicting claims. Although the Russian authorities have claimed that it was Georgia that started the war by launching an unprovoked attack, many reports and researchers (among them independent Russian experts) concluded that the conflict actually started earlier than claimed and that Russia was responsible for provoking the war. On 8 August 2012, Russian president Vladimir Putin told a group of journalists that Russia came up with a plan for its war against Georgia already in 2006 and that it was training the separatist militia to fight against the Georgian government as part of that subversive effort. Putin further stated that "this is no secret".
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.